Products

Guardant360
Guardant Health
Drug Discovery & Research
Guardant360 by Guardant Health is a clinically validated liquid biopsy test that provides AI-enhanced genomic and epigenomic insights from a blood sample to guide oncologists in therapy decisions and clinical trial identification for cancer patients.

See all 1 product →

About Guardant Health

Guardant Health is a leading precision oncology company dedicated to transforming cancer care through innovative blood and tissue tests, real-world data, and advanced AI analytics. The company’s mission is to provide critical insights that empower physicians to make more informed decisions across the entire cancer care continuum, ultimately aiming to give every person more time free from cancer.

For physicians, Guardant Health offers a comprehensive suite of products designed to address various stages of cancer management. This includes tests like Guardant360® CDx for comprehensive genomic profiling in advanced solid tumor cancers, aiding in treatment selection and monitoring response to therapy. Guardant Reveal™ is utilized for molecular residual disease (MRD) detection and recurrence monitoring in early-stage colorectal, breast, and lung cancers following curative-intent therapy. Additionally, the Shield™ blood test, which received FDA approval, provides a less invasive option for colorectal cancer screening in average-risk, asymptomatic adults, aiming to increase screening rates and detect cancer earlier.

Guardant Health’s approach leverages the power of liquid biopsies, which can overcome limitations of traditional tissue biopsies such as invasiveness, potential delays, and insufficient tissue availability. By analyzing circulating tumor DNA (ctDNA) from a simple blood draw, their tests provide a more complete genomic picture, enabling earlier intervention, guiding treatment adjustments, and accelerating drug development for the next generation of precision medicines.

Focus Areas

Liquid Biopsy Precision Oncology Cancer Detection Early Cancer Screening Therapy Selection Molecular Residual Disease Testing Real-World Data AI Analytics Companion Diagnostics

Business Intelligence

Key InvestorsLightspeed Venture Partners, Sequoia Capital, SoftBank Vision Fund, OrbiMed, Khosla Ventures, 8VC
PartnershipsMerck (companion diagnostics and cancer therapies) [cite: 3 (from previous search)], Trial Library (cancer clinical trial access) [cite: 18 (from previous search)], Zephyr AI (drug response predictions and biomarker insights) [cite: 20 (from previous search)], PathGroup (Shield blood test distribution) [cite: 22 (from previous search)], American Cancer Society (cancer screening access and health equity) [cite: 25 (from previous search)], Quest Diagnostics (Shield blood test distribution) [cite: 28 (from previous search)], Pfizer (new cancer therapies using Guardant Infinity Smart Liquid Biopsy Platform) [cite: 27 (from previous search)], Adicon Holdings Limited (Guardant tests for clinical trials in China) [cite: 27 (from previous search)]
AcquisitionsMetaSight Diagnostics (Feb 2026) [cite: 9 (from previous search), 15 (from previous search), 26 (from previous search), 30 (from previous search), 41 (from previous search)], Guardant Health AMEA (Jun 2022) [cite: 1 (from previous search), 11 (from previous search), 15 (from previous search), 29 (from previous search)], Bellwether Bio (Mar 2019) [cite: 15 (from previous search)]
TechnologyGuardant Infinity™ Smart platform, liquid biopsy technology, advanced analytics, AI analytics, Digital Sequencing™
FDA Clearances2+ cleared products (estimated)

What Physicians Need to Know

Liquid Biopsy & Precision Oncology
Guardant Health is a leader in precision oncology, leveraging liquid biopsy to provide critical insights across the entire cancer care continuum. Their portfolio includes Guardant360u00ae Liquid for comprehensive genomic and epigenomic profiling in advanced cancers, Guardant360u00ae CDx as an FDA-approved companion diagnostic, and Guardant Revealu00ae for molecular residual disease (MRD) detection and recurrence monitoring.
Early Cancer Screening & Detection
The Shieldu2122 blood test, an FDA-approved methylation partitioning cell-free DNA (mp-cfDNA) test, offers a convenient and less invasive option for colorectal cancer screening in average-risk adults. Guardant Health is also involved in studies like the NCI Vanguard study to evaluate multi-cancer detection technologies for various cancer types, including lung, breast, and colorectal.
Therapy Selection & Monitoring
Guardant360u00ae CDx provides rapid (results in 5-7 days) and comprehensive genomic profiling to identify actionable biomarkers for targeted therapy selection in advanced solid tumors, with multiple FDA approvals for specific therapies in NSCLC, breast, and colorectal cancers. Guardant Revealu00ae is expanded to include late-stage therapy response monitoring, tracking epigenomic signals to predict outcomes sooner than imaging.
Molecular Residual Disease (MRD) Testing
Guardant Revealu00ae offers a tissue-free, highly sensitive blood test for MRD detection and recurrence monitoring in early-stage colorectal, breast, and lung cancers. It utilizes circulating tumor DNA (ctDNA) to detect cancer at the molecular level, informing adjuvant treatment decisions and monitoring recurrence.
Real-World Data & AI Analytics
Guardant Health's InfinityAI platform and collaborations (e.g., with COTA, Zephyr AI) leverage extensive real-world longitudinal serial testing datasets and AI/ML to generate high-quality evidence, accelerate drug development, identify novel biomarkers, and optimize treatment strategies across all stages of cancer.
Companion Diagnostics
Guardant360u00ae CDx is FDA-approved as a companion diagnostic for several targeted therapies in NSCLC (e.g., Tagrissou00ae, RYBREVANTu2122, LUMAKRASu2122) and for ESR1 mutations in breast cancer. Guardant Health actively collaborates with biopharma companies to develop new companion diagnostics.
Physician Tip

For physicians, Guardant Health's tests offer several advantages: nn* **Actionable Insights:** Rapid and comprehensive genomic and epigenomic profiling from a simple blood draw provides actionable information for therapy selection, even when tissue is limited or difficult to obtain.n* **Overcoming Tissue Biopsy Limitations:** Liquid biopsies reduce the need for invasive tissue biopsies, minimize delays in treatment, and can capture tumor heterogeneity and evolving mutations more effectively.n* **Early Detection & Monitoring:** The Shieldu2122 test provides a convenient screening option for colorectal cancer, potentially increasing adherence. Guardant Revealu00ae enables earlier detection of molecular residual disease and recurrence, allowing for timely intervention.n* **Comprehensive Patient Management:** The Guardant Completeu00ae portfolio supports patient care across screening, early-stage, and advanced cancer, offering a holistic view of the disease.n* **Access to Clinical Trials:** Partnerships and AI-powered platforms (like InfinityAI and collaboration with Trial Library) can help identify eligible patients for precision oncology clinical trials, broadening access to novel therapies.n* **Broad Coverage:** Many Guardant tests are broadly covered by Medicare and major private insurers, ensuring accessibility for a large patient population.

Guardant Health actively integrates its technologies and data through strategic collaborations. They partner with biopharmaceutical companies (e.g., Merck, Boehringer Ingelheim, AstraZeneca, Janssen, Amgen, Daiichi Sankyo) for companion diagnostic development, clinical trial enrollment, and accelerating new cancer therapies. Their real-world data and AI analytics, powered by InfinityAI, are utilized in partnerships with companies like COTA and Zephyr AI to advance precision oncology research, biomarker discovery, and drug response predictions. Furthermore, collaborations with organizations like Trial Library aim to enhance patient access to cancer clinical trials by integrating genomic insights with AI-powered matching platforms.

Products by Guardant Health

1 product in the directory

Guardant360
Guardant Health
Drug Discovery & Research
Guardant360 by Guardant Health is a clinically validated liquid biopsy test that provides AI-enhanced genomic and epigenomic insights from a blood sample to guide oncologists in therapy decisions and clinical trial identification for cancer patients.

What the Web Says

Guardant Health is a biotechnology company specializing in liquid biopsy tests for cancer detection and treatment guidance. Their products, such as Guardant360 and Guardant Reveal, are generally well-regarded by patients and some healthcare professionals for their utility in guiding treatment decisions and providing insights into cancer mutations. However, employer reviews indicate a mixed to negative sentiment regarding work-life balance, management, and company culture, with some employees praising benefits and coworkers while others report high stress and disorganization.

Overall: Mixed

Strengths

  • Products like Guardant360 are helpful in guiding cancer treatment and identifying mutations.
  • Tests can provide critical insights into disease drivers through advanced blood and tissue tests.
  • Good benefits and pay are often cited by employees.
  • Some employees find their immediate teams and coworkers to be superb.
  • The company's mission to conquer cancer with data is seen as ambitious and impactful.
  • Guardant Health tests like Shield for colorectal cancer screening have shown high sensitivity and specificity.

Limitations

  • Poor work-life balance and long hours are frequently mentioned by employees.
  • Management is often described as disorganized, setting unrealistic goals, and lacking support.
  • Company culture can be toxic, with issues of nepotism, favoritism, and a lack of concern for employee well-being.
  • Concerns about job security and recent layoffs have been raised.
  • Some patients have experienced issues with insurance coverage and unexpected high costs for tests.
  • Technical difficulties and delays in accessing test results on the patient portal have been reported.

Based on reviews from: Indeed.com, SimplyHired, Comparably, Reddit, Colorectal Cancer Alliance, Wikipedia, Reuters, YouTube

Last updated: 2026-07-22

Videos

News, demos, and interviews about Guardant Health.

Loading videos...

Videos load interactively. If none appear, search YouTube for Guardant Health →

View all on YouTube

Press & Coverage

Guardant Health
UnitedHealth Group Now Covers Guardant Health's Shield Blood Test for Colorectal Cancer Screening
UnitedHealth Group has expanded coverage to include Guardant Health's Shield blood test for colorectal cancer screening for eligible members aged 45 or older, making it the first major commercial insurer to do so. This is a significant milestone in increasing access to colorectal cancer screening, especially with rising rates in younger populations.
2026-07
Guardant Health
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOSu00ae
The FDA has approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOSu00ae (zongertinib tablets), the first targeted therapy for adults with HER2-mutant advanced non-small cell lung cancer. This approval allows the liquid biopsy test to identify patients eligible for this new treatment.
2026-06
Guardant Health Investor Relations
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health received FDA approval for its new Guardant360 Liquid CDx, which integrates genomic and epigenomic insights to provide a more comprehensive view of cancer from a blood draw. This expanded liquid biopsy panel is approved as a companion diagnostic for multiple therapies in non-small cell lung cancer, colorectal cancer, and advanced breast cancer.
2026-05
Guardant Health
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
Guardant Health and its collaborators are set to present 38 abstracts at the 2026 ASCO Annual Meeting, showcasing the broad clinical utility and advancements of their liquid biopsy tests, which are powered by InfinityAI.
2026-05
Business Wire
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinityu2122 Platform
Guardant Health has entered a multi-year strategic collaboration with Nuvalent to develop companion diagnostics and support the potential commercialization of Nuvalent's oncology pipeline. This partnership will utilize Guardant's Infinityu2122 platform for both tissue and liquid offerings.
2026-04
BioXconomy
Guardant Health is set to acquire MetaSight Diagnostics for $59m - BioXconomy
Guardant Health is acquiring MetaSight Diagnostics for $59 million, with an additional $90 million in milestone payments. This acquisition aims to enhance Guardant's Shield blood test for colorectal cancer screening by integrating MetaSight's metabolomics and lipidomics capabilities.
2026-02
Guardant Health
Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month
Guardant Health launched a Community Colorectal Cancer Screening Grant Program to support community-led efforts in expanding access to colorectal cancer screening. The program provides up to 100 Shield tests per organization to increase screening participation.
2026-02
Guardant Health
Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights
Guardant Health and Zephyr AI have formed a strategic partnership to leverage AI and multimodal molecular data to identify novel biomarkers and accelerate drug development for targeted cancer therapies. This collaboration aims to deliver scalable and actionable insights for biopharmaceutical innovation.
2025-10

Frequently Asked Questions

Guardant Health's liquid biopsy tests, such as Guardant360 CDx and Guardant360 Liquid, provide comprehensive genomic profiling from a simple blood draw, offering molecular insights for therapy selection in advanced cancer patients. These tests can be integrated into Electronic Medical Record (EMR) systems to streamline ordering, track status, and deliver results directly into patient charts, thereby improving clinical workflows.
Guardant Health's early cancer screening approach includes the FDA-approved Shieldu2122 blood test for primary colorectal cancer screening in average-risk adults. The large-scale ECLIPSE study demonstrated the Shield test's efficacy with 84% sensitivity for detecting colorectal cancer and 90% specificity, leading to its inclusion in NCCN CRC Screening Guidelines.
Yes, Guardant Health's Guardant Revealu00ae blood test is specifically designed for molecular residual disease (MRD) detection and recurrence monitoring in early-stage colorectal, breast, and lung cancers. Studies have shown that detecting circulating tumor DNA (ctDNA) with Guardant Reveal after curative-intent treatment can more precisely identify recurrence risk and inform adjuvant therapy decisions, often earlier than traditional methods.
Guardant Health ensures accuracy through clinically validated tests, with Guardant360 CDx being FDA-approved and receiving Advanced Diagnostic Laboratory Test (ADLT) status from CMS. The company is committed to regulatory compliance, including HIPAA and GDPR, and employs state-of-the-art security tools and processes to protect patient data confidentiality and integrity.
Guardant Health has strategic multi-year partnerships with pharmaceutical companies like Merck and Pfizer to develop companion diagnostics and support the commercialization of new cancer therapies. These collaborations leverage Guardant's liquid biopsy portfolio and Infinity Smart platform to identify biomarkers, accelerate drug development, and improve patient access to targeted therapies by providing critical molecular insights for clinical trials.
Guardant Health's FDA-approved tests, such as Guardant360 CDx and Shield, have received Advanced Diagnostic Laboratory Test (ADLT) status from CMS, establishing specific Medicare reimbursement rates. The Guardant Access program offers comprehensive support for practices and patients, managing the billing process, verifying insurance eligibility, and providing financial assistance to limit out-of-pocket expenses.
Guardant Health utilizes its InfinityAI platform to leverage real-world data and AI analytics, integrating large-scale, multimodal, and longitudinal genomic and clinical data. This platform helps identify novel biomarker-defined patient populations, accelerates drug development for biopharma partners, and generates real-world evidence to inform treatment decisions and expand access to targeted therapies.
Guardant Health's long-term vision is to transform cancer care globally by creating affordable and accessible screening and diagnostic tools, driven by a mission to conquer cancer with data. The company demonstrates financial stability through strong revenue growth, such as 31% in Q2 2025, and significant investments in its commercial infrastructure, with analysts generally optimistic about its long-term growth and leadership in liquid biopsy.

Investors

Who's funded Guardant Health.

Related Companies

Visiopharm is a leading provider of AI-driven precision pathology software, catering to both research and diagnostic applications. For physicians, Visiopharm offers advanced tools that transform pathology through image analysis, aiming to enhance precision and productivity in pathology labs. The company has developed nine diagnostic algorithms cleared under IVDR for EU and UK customers, which provide […]

TSI (Transworld Systems Inc.) is a long-standing company primarily known for its debt collection and business process outsourcing services. While they serve various industries, including healthcare, their core offering is focused on accounts receivable management and collections rather than healthcare-specific AI development. They provide solutions to help healthcare providers manage patient accounts, improve cash flow, […]

TrialX is a healthcare AI company specializing in clinical research and space health informatics. The company develops platforms designed to connect patients with clinical trials and facilitate research data collection. Their offerings include an enterprise patient recruitment platform (iConnect) that provides a clinical trials finder (Dory), study website builders, pre-screeners, referral tracking, and volunteer registries. […]

Thinkitive is a global IT services and solutions company that specializes in digital transformation, enterprise application services, outsourced product development, and a testing center of excellence. For physicians, Thinkitive offers a range of AI-driven healthcare solutions designed to streamline clinical and administrative workflows, enhance patient care, and improve operational efficiency. Their services include custom healthcare […]

Taction Software is a U.S.-based healthcare IT and custom software development company specializing in HIPAA-compliant solutions. They build AI-powered applications for healthcare, ranging from rapid clinical AI prototypes to production-grade systems with EHR integration, ambient documentation, and predictive analytics. The company focuses on transforming healthcare delivery through secure, compliant, and innovative software solutions that aim […]

SUPERWISE offers an enterprise AI governance and operations platform designed to help organizations, including those in healthcare, deploy and manage autonomous AI systems with oversight and control. The platform addresses governance, compliance, and operational challenges associated with AI and machine learning deployments. It features real-time guardrails for AI systems, model observability capabilities, and compliance automation, […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.